University of Surrey

Test tubes in the lab Research in the ATI Dance Research

A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer

McNeish, IA, Ledermann, JA, Webber, L, James, L, Kaye, SB, Hall, M, Hall, G, Clamp, A, Earl, H, Banerjee, Saikat , Kristeleit, R, Raja, F, Feeney, A, Lawrence, C, Dawson-Athey, L, Persic, M and Khan, I (2014) A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer Annals of Oncology, 25 (10). pp. 1988-1995.

[img] Text
Ann Oncol-2014-McNeish-1988-95.pdf - Version of Record
Restricted to Repository staff only
Available under License : See the attached licence file.

Download (221kB)
[img]
Preview
Text (licence)
SRI_deposit_agreement.pdf
Available under License : See the attached licence file.

Download (33kB) | Preview

Abstract

Background: We investigated whether the Src inhibitor saracatinib (AZD0530) improved efficacy of weekly paclitaxel in platinum-resistant ovarian cancer. Patients and methods: Patients with platinum-resistant ovarian, fallopian tube or primary peritoneal cancer were randomised 2 : 1 to receive 8-week cycles of weekly paclitaxel (wPxl; 80 mg/m2/week ×6 with 2-week break) plus saracatinib (S; 175 mg o.d.) or placebo (P) continuously, starting 1 week before wPxl, until disease progression. Patients were stratified by taxane-free interval (<6 versus ≥6 months/no prior taxane). The primary end point was progression-free survival (PFS) rate at 6 months. Secondary end points included overall survival (OS) and response rate (RR). Results: A total of 107 patients, median age 63 years, were randomised. Forty-three (40%) had received >2 lines of prior chemotherapy. The 6-month PFS rate was 29% (wPxl + S) versus 34% (wPxl + P) (P = 0.582). Median PFS was 4.7 versus 5.3 months (hazard ratio 1.00, 95% confidence interval 0.65–1.54; P = 0.99). RR (complete + partial) was 29% (wPxl + S) versus 43% (wPxl + P), P value = 0.158. Grade 3/4 adverse events were 36% versus 31% (P = 0.624); the most frequent G3/4 toxicities were vomiting (5.8% saracatinib versus 8.6% placebo), abdominal pain (5.8% versus 0%) and diarrhoea (4.3% versus 5.7%). Febrile neutropenia was more common in the saracatinib arm (4.3%) than placebo (0%). Response, PFS and OS were all significantly (P < 0.05) better in patients with taxane interval ≥6 months/no prior taxane (n = 85) than those <6 months (n = 22), regardless of randomisation. Conclusions: Saracatinib does not improve activity of weekly paclitaxel in platinum-resistant ovarian

Item Type: Article
Subjects : Medical Science
Divisions : Faculty of Health and Medical Sciences > School of Biosciences and Medicine
Authors :
NameEmailORCID
McNeish, IAUNSPECIFIEDUNSPECIFIED
Ledermann, JAUNSPECIFIEDUNSPECIFIED
Webber, LUNSPECIFIEDUNSPECIFIED
James, LUNSPECIFIEDUNSPECIFIED
Kaye, SBUNSPECIFIEDUNSPECIFIED
Hall, MUNSPECIFIEDUNSPECIFIED
Hall, GUNSPECIFIEDUNSPECIFIED
Clamp, AUNSPECIFIEDUNSPECIFIED
Earl, HUNSPECIFIEDUNSPECIFIED
Banerjee, SaikatS.Banerjee@surrey.ac.ukUNSPECIFIED
Kristeleit, RUNSPECIFIEDUNSPECIFIED
Raja, FUNSPECIFIEDUNSPECIFIED
Feeney, AUNSPECIFIEDUNSPECIFIED
Lawrence, CUNSPECIFIEDUNSPECIFIED
Dawson-Athey, LUNSPECIFIEDUNSPECIFIED
Persic, MUNSPECIFIEDUNSPECIFIED
Khan, IUNSPECIFIEDUNSPECIFIED
Date : 1 October 2014
Funders : Cancer Research UK
Identification Number : 10.1093/annonc/mdu363
Copyright Disclaimer : © The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Uncontrolled Keywords : Life Sciences & Biomedicine, Oncology, ovarian cancer, weekly paclitaxel, platinum-resistant, Src, taxane-free-interval, SRC TYROSINE KINASE, SOLID TUMORS
Related URLs :
Depositing User : Symplectic Elements
Date Deposited : 20 Jul 2016 16:51
Last Modified : 27 Jul 2017 15:21
URI: http://epubs.surrey.ac.uk/id/eprint/811219

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year


Information about this web site

© The University of Surrey, Guildford, Surrey, GU2 7XH, United Kingdom.
+44 (0)1483 300800